Clinical Trials
Clinical trials are essential to finding new and better ways to treat disease. By testing medicines in development, these studies help determine whether a potential therapy is safe and effective. None of this is possible without the partnership of patients who choose to participate.
Important: Budoprutug and CLYM116 are investigational therapies and have not yet been approved by any regulatory agency. Only your doctor can determine if a clinical trial may be right for you.
CLYM116 in normal healthy volunteers
ID: NCT07248865
Phase: Phase 1
Status: Active, Recruiting
Description: This is a Phase 1, randomized, double-blind, placebo-controlled, single-center study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CLYM116 in normal healthy adult volunteers.
CLYM116 / MIL116 in normal healthy volunteers and IgA nephropathy patients
ID: NCT07375758
Phase: Phase 1/2
Status: Active, Recruiting
Description: This is a Phase 1/2 study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous CLYM116/MIL116 in healthy participants and patients with IgA nephropathy.
Budoprutug in patients with primary membranous nephropathy (pMN)
ID: NCT07096843
Phase: Phase 2
Status: Active, Recruiting
Description: The PrisMN trial is a Phase 2, open-label, multicenter study evaluating the safety, pharmacodynamics, and preliminary efficacy of three intravenous (IV) dose regimens of budoprutug in adult subjects with pMN.
Budoprutug in patients with immune thrombocytopenia (ITP)
ID: NCT07043946
Phase: Phase 1b
Status: Active, Recruiting
Description: This Phase 1b/2a, open-label, sequential-cohort, dose escalation and expansion study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical effectiveness of budoprutug in subjects with ITP.
Budoprutug in patients with systemic lupus erythematosus (SLE) – Global Study
ID: NCT07011043
Phase: Phase 1b
Status: Active, Recruiting
Description: This Phase 1b, open-label single-ascending-dose study will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and early indications of efficacy of budoprutug in SLE.
Budoprutug in patients with systemic lupus erythematosus (SLE) – China Study
ID: NCT07564596
Phase: Phase 1b/2a
Status: Active, Recruiting
Description: This Phase 1b/2a, open-label and dose-expansion study will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics and early indications of efficacy of budoprutug in SLE.
Budoprutug subcutaneous (SC) vs. IV injection in healthy volunteers
ID: NCT07090655
Phase: Phase 1
Status: Active, Not Recruiting
Description: This Phase 1, randomized, double-blind, placebo-controlled single-ascending-dose study is designed to evaluate the safety, tolerability, PK and PD of budoprutug SC in normal healthy adult volunteers.